Resources
New White Paper: How can Belgium strengthen its position in Advanced Therapies
How Belgium can turn advanced therapy expertise into lasting competitive advantage
Belgium combines academic excellence, clinical research strength, biomanufacturing experience and specialist logistics. Bringing these assets together more effectively could accelerate the development of Advanced Therapy Medicinal Products and generate wider value for patients and the life sciences sector.
This new Deloitte x BioWin White Paper provides an overview of the global ATMP landscape and Belgium’s position within it. It highlights the country’s key strengths and remaining gaps, identifies four priority areas for differentiation, and explores how stronger coordination and targeted investment could help turn existing expertise and assets into scalable solutions with greater impact for patients.